Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 12:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: hydrochlorothiazide tablets Clear all
Completed Phase 3 Interventional Results available

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

NCT03387657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Hydrochlorothiazide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

NCT01692301
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions

NCT01102465
View directory record Official record
Conditions
Hypertension
Interventions
losartan potassium hydrochlorothiazide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

NCT00412932
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
65 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2009 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Not applicable Interventional Results available

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

NCT00478335
View directory record Official record
Conditions
Nephrogenic Diabetes Insipidus
Interventions
sildenafil, calcitonin, hydrochlorothiazide/amiloride, indomethacin, Placebo for sildenafil, placebo for calcitonin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 25 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 2 Interventional Results available

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

NCT00976495
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo, Hydrochlorothiazide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Anaheim, California • Lomita, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 17, 2026, 12:32 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

NCT01432106
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions

NCT00990301
View directory record Official record
Conditions
Healthy
Interventions
Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc., Uniretic® 15mg/25mg Tablets
Drug
Lead sponsor
Paddock Laboratories, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

NCT01712126
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan and Hydrochlorothiazide, Avalide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00846365
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
70
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hueytown, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg

NCT00649441
View directory record Official record
Conditions
Healthy
Interventions
Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Accuretic™ Tablets 20 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

NCT01033071
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
84
States / cities
Gulf Shores, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

Valsartan Intensified Primary Care Reduction of Blood Pressure Study

NCT00902304
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care, Valsartan, Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

NCT00791258
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions

NCT00778726
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2008 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

NCT00654745
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
21
States / cities
Los Angeles, California • Sylmar, California • Tustin, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

NCT06205407
View directory record Official record
Conditions
Healthy Participants
Interventions
Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions

NCT00778674
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2008 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Salt Loading and Thiazide Intervention Study

NCT00896389
View directory record Official record
Conditions
Hypertension
Interventions
Salt loading, Hydrochlorothiazide (HCTZ)
Procedure · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

NCT00942994
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 3 Interventional

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

NCT00095394
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan/HCTZ, Irbesartan monotherapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
156
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 153 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

NCT01149486
View directory record Official record
Conditions
Healthy
Interventions
Losartan potassium/Hydrochlorothiazide, Hyzaar®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 17, 2026, 12:32 AM EDT
Completed Phase 4 Interventional Results available

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

NCT00931710
View directory record Official record
Conditions
Stage 2 Systolic Hypertension
Interventions
valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 17, 2026, 12:32 AM EDT